Recent knockout studies, suggested that inhibition of TXNIP/TBP-2, up regulates both insulin sensitivity and glucose-stimulated insulin secretion in diabetes, and might present a novel therapeutic approach for T2DM [13], [45]. Here, TBPL2 is linked to type 2 diabetes mellitus.